Wolverine Trading’s Cardiff Oncology CRDF Stock Holding History

Wolverine Trading’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$84.4K	Sell	40,600 -6,300	-13%	-$17.4K	﹤0.01%	5259
2025 Q2	$148K	Buy	46,900 +29,300	+166%	+$89.4K	﹤0.01%	4044
2025 Q1	$57.9K	Buy	17,600 +3,300	+23%	+$13.1K	﹤0.01%	4387
2024 Q4	$60.9K	Sell	14,300 -1,300	-8%	-$4.06K	﹤0.01%	4933
2024 Q3	$43.2K	Sell	15,600 -20,200	-56%	-$47.7K	﹤0.01%	4557
2024 Q2	$79.5K	Sell	35,800 -2,800	-7%	-$10.6K	﹤0.01%	4127
2024 Q1	$206K	Buy	+38,600	New	+$103K	﹤0.01%	3778
2023 Q4	–	Sell	-14,500	Closed	-$20.2K	–	4587
2023 Q3	$20.2K	Buy	+14,500	New	+$24.5K	﹤0.01%	4320
2022 Q1	–	Sell	-10,800	Closed	-$67K	–	5553
2021 Q4	$67K	Buy	+10,800	New	+$64.4K	﹤0.01%	5234
2021 Q3	–	Sell	-15,000	Closed	-$108K	–	6348
2021 Q2	$108K	Buy	+15,000	New	+$127K	﹤0.01%	5369

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wolverine Trading's CRDF Position: Q3 2025 in Review

Wolverine Trading sold out of Cardiff Oncology (CRDF) in Q3 2025, closing a stake of 14,573 shares — an estimated $40.3K sold.

Wolverine Trading first reported a position in CRDF in Q4 2016 and held it in 7 quarters. The position peaked at $104K in Q4 2024. 112 funds tracked by Wall St. Rank hold CRDF as of Q3 2025.

Wolverine Trading reported no remaining Cardiff Oncology position as of Q3 2025 after selling out during the quarter.
Wolverine Trading sold 14,573 Cardiff Oncology shares in Q3 2025, an estimated $40.3K.
Wolverine Trading first reported a position in Cardiff Oncology in Q4 2016 and held it in 7 quarters.
Wolverine Trading's Cardiff Oncology position peaked at $104K in Q4 2024.
112 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.